JPY 463.0
(2.89%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 61.11 Million JPY | -83.68% |
2022 | 374.47 Million JPY | -47.13% |
2021 | 708.24 Million JPY | 415.15% |
2020 | 137.48 Million JPY | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 7.29 Million JPY | -32.09% |
2024 Q1 | 10.74 Million JPY | -65.76% |
2023 Q4 | 31.38 Million JPY | 173.92% |
2023 FY | 61.11 Million JPY | -83.68% |
2023 Q3 | 11.45 Million JPY | 2.28% |
2023 Q2 | 11.2 Million JPY | 58.44% |
2023 Q1 | 7.07 Million JPY | -79.03% |
2022 FY | 374.47 Million JPY | -47.13% |
2022 Q4 | 33.72 Million JPY | 308.7% |
2022 Q3 | 8.25 Million JPY | 0.0% |
2021 FY | 708.24 Million JPY | 415.15% |
2020 FY | 137.48 Million JPY | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 62.14 Billion JPY | 99.902% |
Takeda Pharmaceutical Company Limited | 4263.76 Billion JPY | 99.999% |
Sumitomo Pharma Co., Ltd. | 314.55 Billion JPY | 99.981% |
Shionogi & Co., Ltd. | 435.08 Billion JPY | 99.986% |
Wakamoto Pharmaceutical Co.,Ltd. | 7.73 Billion JPY | 99.21% |
Nippon Shinyaku Co., Ltd. | 148.25 Billion JPY | 99.959% |
Kaken Pharmaceutical Co., Ltd. | 72.04 Billion JPY | 99.915% |
Eisai Co., Ltd. | 741.75 Billion JPY | 99.992% |
Morishita Jintan Co., Ltd. | 12.4 Billion JPY | 99.507% |
Hisamitsu Pharmaceutical Co., Inc. | 141.7 Billion JPY | 99.957% |
Mochida Pharmaceutical Co., Ltd. | 102.88 Billion JPY | 99.941% |
Fuso Pharmaceutical Industries,Ltd. | 55.4 Billion JPY | 99.89% |
Nippon Chemiphar Co., Ltd. | 30.74 Billion JPY | 99.801% |
Tsumura & Co. | 150.84 Billion JPY | 99.959% |
Kissei Pharmaceutical Co., Ltd. | 75.57 Billion JPY | 99.919% |
Torii Pharmaceutical Co., Ltd. | 54.63 Billion JPY | 99.888% |
Towa Pharmaceutical Co., Ltd. | 227.93 Billion JPY | 99.973% |
Fuji Pharma Co., Ltd. | 40.88 Billion JPY | 99.851% |
Zeria Pharmaceutical Co., Ltd. | 75.72 Billion JPY | 99.919% |
KYORIN Holdings, Inc. | 119.53 Billion JPY | 99.949% |
Taiko Pharmaceutical Co.,Ltd. | 5.04 Billion JPY | 98.787% |
Daito Pharmaceutical Co.,Ltd. | 46.89 Billion JPY | 99.87% |
SymBio Pharmaceuticals Limited | 5.58 Billion JPY | 98.907% |
MedRx Co., Ltd | 26 Million JPY | -135.046% |
Mizuho Medy Co.,Ltd. | 10.98 Billion JPY | 99.444% |
Solasia Pharma K.K. | 617 Million JPY | 90.095% |
Modalis Therapeutics Corporation | - JPY | -Infinity% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 62.84 Billion JPY | 99.903% |
Sawai Group Holdings Co., Ltd. | 176.86 Billion JPY | 99.965% |
Toho Holdings Co., Ltd. | 1476.71 Billion JPY | 99.996% |
Koa Shoji Holdings Co.,Ltd. | 22.13 Billion JPY | 99.724% |